How Testosterone Cypionate Affects Haematocrit

Testosterone cypionate and testosterone enanthate deliver identical hormone. The only chemical difference is the ester attached at the 17-beta position, which is cleaved off before the hormone reaches any receptor. Once that ester is removed, the molecule circulating in your blood is testosterone in both cases.

The erythropoietic mechanism is therefore the same as for any injectable testosterone ester:

1. EPO upregulation: Testosterone increases renal erythropoietin production, signalling the bone marrow to make more red blood cells.
2. Hepcidin suppression: Androgens suppress hepcidin, the master iron-regulatory hormone, increasing iron availability for haemoglobin synthesis.
3. Direct marrow stimulation: Androgens act on erythroid progenitor cells directly, promoting proliferation and differentiation.

What is genuinely different about cypionate: very little. The cypionate ester is slightly heavier than the enanthate ester, so 100 mg of testosterone cypionate delivers roughly 70 mg of testosterone versus roughly 72 mg from testosterone enanthate, a difference of about 3%. Commonly quoted terminal half-lives differ slightly, with enanthate around 4.5 days and cypionate sometimes quoted longer, but Schulte-Beerbühl and Nieschlag (1980, PMID 7353699) compared serum testosterone, DHT, LH and FSH directly after injection of the two esters, and the Endocrine Society's 2018 clinical practice guideline (PMID 29562364) doses them identically at 75 to 100 mg weekly or 150 to 200 mg every two weeks intramuscularly, drawing no distinction between them.

What actually drives your haematocrit is dose and injection frequency, not the ester. Larger, less frequent injections produce higher peak testosterone concentrations, and peak concentration is what drives the EPO response.

Replacement doses (100-200 mg/week):

• Haematocrit typically rises 2 to 5 percentage points within the first 3 to 6 months
• Most men stabilise between 48% and 52%
• Roughly 10 to 20% exceed 54%, the threshold at which intervention is conventionally recommended

Supraphysiological doses (300-600+ mg/week):

• Haematocrit can rise 5 to 10 percentage points or more
• Values of 54 to 58% are common
• The rise is faster, often visible by week 6 to 8

Injection frequency matters more than the ester:

• 200 mg once every two weeks produces a much higher peak than 100 mg weekly or 50 mg twice weekly, and the higher peak drives a larger EPO response.
• McFarland (2017, PMID 29264562) measured weekly subcutaneous testosterone cypionate at eight time points across the dosing interval and found total testosterone stable and within range throughout, averaging 627 ng/dL. Stable levels are the mechanism by which frequent smaller doses blunt the haematocrit rise.

Timing: Begins within 2 to 4 weeks, peaks at 3 to 6 months, then remains elevated for as long as testosterone is administered.

Baseline: Full blood count before starting. Men with haematocrit above 50% at baseline are at higher risk of crossing 54%.

First year: Every 3 months, sampled at trough, meaning immediately before your next injection.

Stable patients: Every 6 months once two consecutive checks have been stable.

Extra monitoring after:

• Any dose increase
• A switch from frequent to infrequent injections
• Adding a second androgen
• Moving to a higher altitude
• Symptoms: headaches, visual disturbance, chest tightness, facial flushing

Switching between esters is not a reason to retest early, because the esters are equivalent. Switching injection frequency is.

If haematocrit is 50-54%:

• Increase injection frequency, for example from weekly to every 3.5 days, to lower peak concentrations
• Confirm adequate hydration, since dehydration falsely elevates haematocrit
• Recheck in 4 to 6 weeks

If haematocrit exceeds 54%:

• Reduce the dose by 10 to 20%
• Split the dose into smaller, more frequent injections
• Therapeutic phlebotomy removes one unit of 450 to 500 mL and typically lowers haematocrit by 3 to 4 points
• Recheck 2 to 4 weeks after phlebotomy

Do not switch from cypionate to enanthate expecting a haematocrit benefit. There is no evidence of a difference between the esters, and the Endocrine Society guideline (PMID 29562364) treats them as interchangeable. Changing frequency or dose is what works.

Watch ferritin if you are donating blood repeatedly: Repeated phlebotomy on top of testosterone-driven erythropoiesis is the fastest route to iron deficiency on TRT.

Further reading: How to lower haematocrit on TRT